Immix Biopharma, Inc. announced that the 1st patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy. The NEXICART-2 study is intended to evaluate the safety and efficacy of NXC-201 in relapsed/refractory AL Amyloidosis patients with adequate cardiac function who have not been exposed to prior BCMA-targeted therapy. The study builds on positive data from the initial ex-U.S. study, NEXICART-1, presented at the 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT 2024) which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients (12/13).

The best responder experienced a 28.0 month duration of response (as reported May 10, 2024, with ongoing follow-up). NXC-201 is the only CAR-T therapy currently in development in AL Amyloidosis, mentioned in a review article entitled ?Systemic Light Chain Amyloidosis? published in June, 2024 New England Journal of Medicine.